AL002 / Alector, AbbVie 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AL002 / Alector, AbbVie
2019-001476-11: A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's Disease

Not yet recruiting
2
328
Europe
AL002, AL002, Solution for infusion
Alector Inc., Alector Inc.
Early Alzheimer’s Disease, Alzheimer’s Disease, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-002987-57: A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's Disease Ensayo clínico para evaluar AL002 en participantes con enfermedad de Alzheimer temprana

Ongoing
2
190
Europe
AL002, AL002, Solution for infusion
Alector, Inc., Alector, Inc.
Early Alzheimer's Disease Enfermedad de Alzheimer temprana, Alzheimer's Disease Enfermedad de Alzheimer, Diseases [C] - Nervous System Diseases [C10]
 
 
INVOKE-2, NCT04592874 / 2019-001476-11: A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Completed
2
381
Europe, Canada, US, RoW
AL002, Placebo
Alector Inc., AbbVie
Alzheimer Disease
08/24
09/24
NCT05744401 / 2022-002987-57: A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Active, not recruiting
2
188
Europe, Canada, US, RoW
AL002
Alector Inc., AbbVie
Alzheimer's Disease
09/25
12/25

Download Options